中国临床药理学杂志2024，Vol.40Issue(14)：2003-2007,5.DOI:10.13699/j.cnki.1001-6821.2024.14.001
胰激肽原酶联合厄贝沙坦治疗老年2型糖尿病肾病患者的临床研究
Clinical trial of pancreatic kallidinogenase combined with irbesartan in the treatment of elderly patients with type 2 diabetic nephropathy
摘要
Abstract
Objective To explore the efficacy of pancreatic kallidinogenase enteric-coated tablet combined with irbesartan tablet in the treatment of elderly patients with type 2 diabetic nephropathy(DN).Methods Elderly patients with type 2 DN were selected as the research subjects,and were randomized into control group and treatment group.The control group was given 150 mg of irbesartan tablets once a day,while the treatment group was given 240 U of pancreatic kallidinogenase enteric-coated tablets three times a day on the basis of the control group.The clinical efficacy,renal function indicators[serum creatinine(SCr),blood urea nitrogen(BUN),urinary albumin excretion rate(UAER)],hemodynamic indicators[fibrinogen(FIB),whole blood viscosity,hematocrit(HCT)],microvascular lesion indicators[vascular endothelial growth factor(VEGF),soluble intercellular adhesion molecule-1(sICAM-1)],B-ultrasound detection indicators[maximum aortic flow velocity(Vmax),minimum diastolic flow velocity(Vmin),resistance index(RI)at the renal hilum]before and after treatment and adverse drug reactions were compared between both groups.Results After treatment,the total effective rates in control group and treatment group were 85.42％and 97.92;SCr levels were(90.47±18.14)and(80.28±12.04)μmol·L-1;BUN levels were(7.24±1.34)and(6.54±1.21)mmol·L-1;UAER levels were(36.17±6.07)and(31.04±5.21)μg·min-1;FIB levels were(4.32±0.59)and(3.95±0.48)g·L-1;whole blood viscosity values were(7.38±1.15)and(6.81±0.98)mPa·s;HCT levels were(38.63±7.01)％and(36.17±6.48)％;VEGF levels were(254.18±45.59)and(212.14±40.48)pg·mL-1;human sICAM-1 levels were(336.40±61.57)and(295.30±58.46)pg·L-1;the Vmax of renal artery were(72.58±3.60)and(74.98±3.78)cm·s-1;the Vmin values were(22.48±3.14)and(24.83±3.63)cm·s-1;the RI values were 0.73±0.06 and 0.68±0.07,respectively.There were statistical differences in the above indicators between control group and treatment group(all P＜0.05).The total incidence eares of adverse drug reactions in control group and treatment group were 4.17％(2 cases/48 cases)and 8.33％(4 cases/48 cases)respectively(P＞0.05).Conclusion Pancreatic kallidinogenase enteric-coated tablet combined with irbesartan tablet can effectively improve the renal function of elderly patients with type 2 DN,improve the blood flow and delay microvascular lesion,and enhance the efficacy,therefore it is safe and effective.关键词
胰激肽原酶肠溶片/厄贝沙坦片/老年2型糖尿病肾病Key words
pancreatic kallidinogenase enteric-coated tablet/irbesartan tablet/elderly type 2 diabetic nephropathy分类
医药卫生引用本文复制引用
曾忠评,曾媛媛,左彬荣,陈坤玉..胰激肽原酶联合厄贝沙坦治疗老年2型糖尿病肾病患者的临床研究[J].中国临床药理学杂志,2024,40(14):2003-2007,5.基金项目
江西省中医药管理局科技计划基金资助项目(2021A108) （2021A108）
